EKF Ekf Diagnostics Holdings Plc

TIDMEKF

RNS Number : 8527L

EKF Diagnostics Holdings PLC

18 May 2022

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

AGM Statement

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business , provides an update to shareholders ahead of its Annual General Meeting ('AGM') today at Harwood Capital, 6 Stratton Street, Mayfair, W1J 8LD at 11.00 a.m.

As previously announced, the Company is providing a facility for shareholders to listen in to the AGM, either online or telephonically (in a non-voting capacity) and investor questions will be addressed afterwards. For dial-in details please contact Walbrook PR via email at ekf@walbrookpr.com or call +44 (0)20 7933 8780.

Chairman's AGM statement

"We were delighted to announce at the end of March a record set of financial results for 2021 and provide confirmation of our ongoing focus on implementing a strategy that positions our business for sustainable future growth.

In the new financial year we have already made good progress in implementing our investment plans to support this growth. We have made significant investment to expand the fermentation capabilities of the Life Sciences business at our South Bend, Indiana, facility. We have a demand-driven pipeline of opportunities that is expected to start flowing strongly once the investment in new fermenters is completed by the end of the current year, and we remain on track to have the capacity in place to support significant revenue growth through to 2024.

We are also making good progress in redeploying our Contract Manufacturing and Laboratory Services capacity and skill set into non-COVID related areas. In Contract Manufacturing we are actively working with new partners to build a strong pipeline for non-COVID products. This includes delivering validation batches for products which are expected to be launched throughout 2022 and into 2023. In Laboratory Services, the ADL Health team are expanding their range of testing capabilities across a broader suite of healthcare applications and are progressing well.

Trading in the first quarter has been strong and we have delivered first quarter revenues in line with that of the corresponding period in 2021, and we remain on track to deliver full year results in line with current market forecasts. In our established Point-of-Care and Central Laboratory businesses we continue to see market growth following the COVID slowdown and in the first quarter have seen sales growth compared with 2021.

As a Board we remain confident in delivering on our growth strategy to 2024 and I would like to thank my fellow shareholders for their support."

 
EKF Diagnostics Holdings plc                                    www.ekfdiagnostics.com 
Mike Salter, CEO                                              Tel: +44 (0)29 2071 0570 
Marc Davies, CFO 
 
Singer Capital Markets (Nominated Adviser &                   Tel: +44 (0)20 7496 3000 
 Joint Broker) 
Aubrey Powell / George Tzimas 
 
Investec Bank plc (Joint Broker)                              Tel: +44 (0)20 7597 4000 
Gary Clarence / Daniel Adams / Ben 
 Farrow 
 
Walbrook PR Limited                     Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Applegarth                Mob: +44 (0)7980 541 893 / +44 (0)7584 
                                                                               391 303 
 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

 
Point-of-Care           Providing a portfolio of Point-of-Care analysers and 
                         consumables, particularly for use in the area of Hematology 
                         and Diabetes, for use in hospital and research laboratories, 
                         doctor's offices, blood banks and for in-field anaemia 
                         screening programmes. EKF has an estimated 80,000 
                         hemoglobin, hematocrit, HbA1c, glucose and lactate 
                         analysers in regular use across more than 100 countries. 
Central Laboratory      Clinical chemistry, Small lab analysers, Centrifuges 
                         Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycates 
                         Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin 
Life Sciences           Enzyme fermentation, Custom products and Bulk fermentation 
Contract Manufacturing  Bulk formulation, Sample collection kits, Private 
                         labelling, Molecular and forensic kits 
Laboratory Services     In September 2021, EKF completed the acquisition of 
                         Advanced Diagnostic Laboratory LLC ("ADL Health") 
                         , a Texas based testing laboratory certified under 
                         the Clinical Laboratory Improvement Amendments ("CLIA") 
                         for high complexity testing. The laboratory provides 
                         testing for a variety of clinical, forensic and microbiological 
                         sample types using a range of analytical techniques. 
                         This acquisition positions EKF as a leading 'one stop' 
                         provider of diagnostic products and services from 
                         sample collection to results. 
 

EKF's growth strategy to 2024 and beyond can be summarised as:

 
--  continuing innovation in products and services in Point-of-Care, 
     Central Laboratory and Life Sciences leveraging new and existing 
     routes to market and relationships; 
--  investment in expanded production and kitting capabilities to offer 
     a suite of diagnostic Contract Manufacturing solutions to third 
     party businesses; 
--  expansion of CLIA Laboratories Testing offering, building on the 
     acquired capabilities in ADL Health; and 
--  concluding complementary earnings-enhancing acquisitions with key 
     strategic value. 
 

EKF will also continue to generate enhanced shareholder value through:

 
--  a progressive dividend policy; and 
--  its agreement with Mount Sinai Innovation Partners ("MSIP"), which 
     allows us advanced access to innovative commercial opportunities 
     and where we can build on the ongoing successes of Renalytix plc, 
     Verici Dx plc and Trellus Health plc. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGMSFSFAWEESEDI

(END) Dow Jones Newswires

May 18, 2022 10:03 ET (14:03 GMT)

Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024